UiPath (PATH)
(Delayed Data from NYSE)
$12.26 USD
+0.19 (1.57%)
Updated May 31, 2024 03:59 PM ET
After-Market: $12.28 +0.02 (0.16%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
[PATH]
Reports for Purchase
Showing records 81 - 100 ( 129 total )
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of Aug. 5
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
August And Remaining 2013 Catalysts For Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
July And Remaining 2013 Catalysts For Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
IHC Presentations Raise Physician Awareness and Support Launch Preparations, in Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 24
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
June And Remaining 2013 Catalysts For Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
Q1 Financials: Runway Guidance Into Q4 Reiterated
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
Emerging Pharmaceuticals-May and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
Emerging Pharmaceuticals - April and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
Q4 Financials: Cash Runway Guidance is into Q4:13; Next: Zecuity Partnership(s) and Commercial Launch; Reiterate OUTPERFORM and $8 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
Emerging Pharmaceuticals-March and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
Outlook For 2013: Manufacturing, Partnership, And Zecuity Launch
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
February and 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
Zecuity Approved In U.S.; Next: Potential Commercial Partnership And Q4 Launch
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
We Anticipate FDA Approval of Zecuity On January 17; A Partnership Announcement Is Likely To Follow
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of December 30.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of December 16
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Products
Q3 Financials: Cash Runway Guidance is into Q4:13.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L